Compare FTF & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTF | OBIO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 238.3M |
| IPO Year | 2003 | 2020 |
| Metric | FTF | OBIO |
|---|---|---|
| Price | $5.85 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 166.6K | ★ 247.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $5.70 | $2.20 |
| 52 Week High | $6.54 | $5.42 |
| Indicator | FTF | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 49.63 |
| Support Level | $5.85 | $3.95 |
| Resistance Level | $5.95 | $4.19 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 23.79 | 64.30 |
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective, is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.